Otsuka Holdings Company Limited operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Otsuka Holdings Company Limited with three other
companies in this sector in Japan:
Daiichi Sankyo Company Limited
sales of 960.20 billion Japanese Yen [US$8.57 billion]
of which 92%
was Prescription drugs),
Astellas Pharma Incorporated
(1.30 trillion Japanese Yen [US$11.61 billion]
of which 45%
was Other), and
Takeda Pharmaceutical Company Limited
(1.77 trillion Japanese Yen [US$15.81 billion]
of which 96%
was Pharmaceutical Business).
During the year ended December of 2018, sales at
Otsuka Holdings Company Limited were ¥1.29 trillion (US$11.54 billion).
increase of 4.2%
versus 2017, when the company's sales were ¥1.24 trillion.
The sales level in 2018 was fairly close to the level five years ago: in 2013, Otsuka Holdings Company Limited had sales
of ¥1.22 trillion.
Sales of Nutraceuticals Related Business saw an increase
7.6% in 2018, from
¥314.65 billion to ¥338.59 billion.
Not all segments of Otsuka Holdings Company Limited experienced an increase in sales in 2018:
sales of Other Businesses fell 10.9% to ¥102.63 billion.
Otsuka Holdings Company Limited also experienced decreases in sales in
Consumer-Related Business (down 4.8% to ¥33.65 billion)